drugset / Trial / NCT04663204
A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy
NaSingle-groupOpen-labelTreatment
Summary
To determine the nephroprotective potential of treatment with sparsentan in (1: Cohort A) patients newly-diagnosed with immunoglobulin A nephropathy (IgAN) (ie, incident patients) who have not received prior angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) therapy, and in (2: Cohort B) patients with recurrent IgAN following kidney transplantation.
Timeline
- Start
- 2020-12-10
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sparsentan | Small molecule | 100 mg | Oral |
| Subject | Sparsentan | Small molecule | 200 mg | Oral |
| Subject | Sparsentan | Small molecule | 400 mg | Oral |